In a 41‑year‑old patient with abdominal ultrasound showing a normal‑sized liver with increased parenchymal echogenicity, no focal lesions, a normal gallbladder, and a non‑dilated common bile duct, what is the most likely diagnosis and what are the recommended next steps?

Diagnosis and Management of Incidental Hepatic Steatosis

The most likely diagnosis is nonalcoholic fatty liver disease (NAFLD), and you should immediately obtain liver function tests, complete blood count, and calculate a FIB-4 score to risk-stratify for clinically significant fibrosis.

Most Likely Diagnosis

Increased parenchymal echogenicity on ultrasound in a 41-year-old with normal liver size and no focal lesions is highly suggestive of hepatic steatosis 1, 2. While increased echogenicity can occasionally represent other conditions (cirrhosis, viral hepatitis, glycogen storage disease, hemochromatosis), hepatic steatosis is by far the most common cause 1. The positive predictive value of increased echogenicity for moderate-to-severe steatosis is 87%, which increases to 93-94% when accompanied by additional findings like high attenuation or reduced portal vessel wall distinction 2.

Critical Next Steps: Two-Tier Risk Stratification

Step 1: Initial Laboratory Evaluation

Obtain the following tests immediately 3:

• Comprehensive metabolic panel (including ALT, AST, albumin) 3
• Complete blood count (for platelet count) 3
• Alcohol screening using validated tools (AUDIT or AUDIT-C) 3
• Hepatitis B and C serologies to exclude viral hepatitis 3

Step 2: Calculate FIB-4 Score for Fibrosis Risk Stratification

Use the FIB-4 score as your first-line noninvasive assessment because it has the best diagnostic accuracy for advanced fibrosis in NAFLD and correlates with clinical outcomes 3. The formula uses age, AST, ALT, and platelet count 3.

Interpret FIB-4 results as follows 3:

• FIB-4 <1.3: Advanced fibrosis excluded (negative predictive value ≥90%); no further immediate workup needed, but consider annual reassessment 3
• FIB-4 ≥1.3: Proceed to second-tier testing with elastography or proprietary scores, and consider hepatology referral 3

Step 3: Address Metabolic Risk Factors

Screen for components of metabolic syndrome 3:

• Type 2 diabetes (HbA1c or fasting glucose) 3
• Dyslipidemia (lipid panel) 3
• Obesity (BMI calculation) 3
• Hypertension (blood pressure measurement) 3

Important Clinical Caveats

Do not rely on ultrasound alone to exclude fibrosis or cirrhosis. Ultrasound cannot reliably detect fibrosis—even cirrhosis can present with normal echogenicity in asymptomatic patients 2. In one study, 5 of 9 patients with septal fibrosis and 4 of 6 with cirrhosis had normal liver echogenicity 2.

Approximately 11% of patients with incidentally discovered hepatic steatosis are at high risk for advanced fibrosis 3. This risk increases substantially if aminotransferases are elevated, as these patients have significantly higher progression rates to cirrhosis and hepatocellular carcinoma 3.

The FIB-4 cutoff differs by age: use <1.3 for patients under 65 years and <2.0 for those 65 and older 3.

When to Refer to Hepatology

Consider specialty referral for 3:

• FIB-4 ≥1.3 (indeterminate or high risk for advanced fibrosis) 3
• Elevated aminotransferases with unclear etiology after initial workup 3
• Evidence of other chronic liver diseases requiring specialized management 3